Loading patent…
AssigneeAmgen Inc.
InventorsIan Foltz, Raffaella Faggioni, Giorgio Senaldi, Kathy Manchulenko, Jaspal Kang, Palaniswami Rathanaswami, Kiran Ahluwalia, Orit Foord, Scott Klakamp
Estimating the term…
The present invention is related to antibodies directed to IL-13 and uses of such antibodies. For example, in accordance with the present invention, there are provided human monoclonal antibodies directed to IL-13. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), are provided. Additionally, methods of using these antibodies to treat patients are also provided. Additionally, IL-13 dependent biomarkers and methods of their identification and use are also provided.
An isolated human antibody that binds to IL-13, wherein the isolated human antibody binds to human IL-13 with a KD of less than 170 pM.
A method of treating an IL-13 related disorder, said method comprising administering an effective amount of a human antibody that binds to IL-13 to a subject in need of treatment, wherein the isolated human antibody binds to IL-13 with a KD of no more than 170 pM.
An isolated human antibody to IL-13, wherein said antibody binds IL-13 and IL-13Q110R with a KD that is less than 170 pM and binds to both IL-13 and IL-13Q110R with KDs that are within 50% of each other.
A method for treating asthma, said method comprising:
A method of treating a symptom of an IL-13 related disorder, said method comprising:
Dependencies are inferred from the claim text.